APA (7th ed.) Citation

Matsumura, Y., Inomata, S., Yamaguchi, H., Mine, H., Takagi, H., Watanabe, M., . . . Suzuki, H. (2021). A patient with ALK‐positive lung adenocarcinoma who survived alectinib‐refractory postoperative recurrence for 4 years by switching to ceritinib. Thoracic Cancer, 12(15), 2225. https://doi.org/10.1111/1759-7714.14058

Chicago Style (17th ed.) Citation

Matsumura, Yuki, et al. "A Patient with ALK‐positive Lung Adenocarcinoma Who Survived Alectinib‐refractory Postoperative Recurrence for 4 years by Switching to Ceritinib." Thoracic Cancer 12, no. 15 (2021): 2225. https://doi.org/10.1111/1759-7714.14058.

MLA (9th ed.) Citation

Matsumura, Yuki, et al. "A Patient with ALK‐positive Lung Adenocarcinoma Who Survived Alectinib‐refractory Postoperative Recurrence for 4 years by Switching to Ceritinib." Thoracic Cancer, vol. 12, no. 15, 2021, p. 2225, https://doi.org/10.1111/1759-7714.14058.